Guide to Medical Marijuana

Marijuana is the most popular recreational substance in Western societies and has the longest recorded history of human use, over 5,000 years. The popularity of marijuana as a recreational substance is due to its ability to alter sensory perception and induce elation and euphoria. In addition to recreational enjoyment, the components of the marijuana plant (Cannabinoids) have a variety of beneficial medicinal effects unrelated to its psychoactive properties that have been recognized for thousands of years.

As early as the third millennium BC, Chinese texts described its usefulness in the relief of pain and cramps. In ancient India, the anxiety-relieving effect of marijuana was recorded more than 3,000 years ago. The use of cannabis or hashish as a psychoactive substance reached Europe and the Americas through the Arab world in the 19th century. During the same period, marijuana extracts had gained widespread use for medicinal purposes until 1937, when concern about the dangers of abuse led to the banning of marijuana for further medicinal use in the United States. In the past 20 years, there has been a resurgence of interest in its medicinal properties of marijuana.

Despite the significant scientific insights into the mechanisms underlying the therapeutic actions of marijuana, there is still widespread misunderstanding as to how Medical Marijuana works and how to use it effectively. As a Medical Marijuana patient for more than 15 years and founder of CBD Science, LLC (1), I am compelled to present the comprehensive research on Medical Marijuana and outline for health care professionals common sense therapies based on that research.

Legal/Political Background
In 2006, the U.S. Food and Drug Administration (FDA) issued an inter-agency advisory memo opposing the use of Medical Marijuana, claiming there is no evidence of its medical benefits. The memo claimed (2);

“...no sound scientific studies support medical use of marijuana for treatment in the United States, and no animal or human data supported the safety or efficacy of marijuana for general medical use.”

In 2011, the Drug Enforcement Administration (DEA) issued a white paper, “The DEA Position on Marijuana,” which claimed (3);

“The clear weight of the currently available evidence supports the position that Marijuana has no accepted medicinal treatment in the United States”

The FDA and the DEA position on Medical Marijuana are based neither on a through scientific review nor any cogent line of logical reasoning. The federal government’s position just doesn’t stand up to scrutiny.

Sound scientific and double blind clinical studies support the medicinal use of Marijuana. The branch of the Federal Government responsible for Medical Science, the National Institute of Health (NIH), is well aware of the medicinal value of Medical Marijuana. In addition to funding many of the studies cited in the footnotes below, the NIH published a paper outlining the value of Medical Marijuana’s compounds in the development of Pharmacotherapy in 2006 (4).

The Federal Government maintains conflicting positions on Medical Marijuana. Common sense demands that we examine the conflicting positions and create a coherent policy. The NIH(5), Department of Health and Human Services (HHS)(6), Veterans Administration (VA)(7), Department of Justice (JOD)(8) Patent Office (PTO)(9), and FDA(10) have taken positions in favor of the medical use of Marijuana, while the DEA (11) and Internal Revenue Service (IRS) (12) have taken positions in opposition to the Medical use of Marijuana.

While the Federal Government re-examines the scientific evidence and sorts out its contradictory positions, Medical Marijuana patients can rest assured that scientific research and rigorous double-blind clinical trials conducted between 2003 and 2012(13) have shown that Medical Marijuana Therapy can treat both the disease and the symptoms of disease without the severe side effects associated with other medications.

GW Pharmaceuticals patents have been accepted by the U.S. Patent Office because they have generated over 1,300 patient-years of safety data, and adverse events have been predictable and well tolerated (14). The most common side effects of Medical Marijuana are dizziness (which occurs mainly in the first few weeks of treatment) and fatigue. These reactions are usually mild to moderate and improve within a few days, even if treatment is continued. These side effects are common to many other prescription medications, particularly pain medications.
What follows is a comprehensive reference for Medical Marijuana therapies backed by sound scientific and clinical double blind studies performed in Israel, Brazil, the Netherlands, Japan, the United Kingdom, and the United States over the past 20 years. Many of these studies were funded by research grants originating in the United States under the oversight of the NIH.

The scientific research and the clinical trials have been done. They have shown that Medical Marijuana can be safe and effective treatment for the diseases and symptoms outlined below. But don’t take my word for it, read the patent applications specified in footnote #13 and decide for yourself.

The wait is over; pain and suffering for millions can be reduced or eliminated right now without severe side effects.

But first, let me clear up some common misconceptions about Medical Marijuana:

- **Myth:** marijuana kills brain cells.
- **Truth:** Medical Marijuana does not kill brain cells. The act of smoking – inhaling and holding your breath – can temporarily reduce one’s brain cells, but that has nothing to do with Medical Marijuana. It has to do with the way you are taking the medicine, i.e. your “Method of Delivery.” Medical Marijuana (regardless of its method of delivery) has Neuro-protective and Antioxidant properties (15).
- **Myth:** Smoking Marijuana is as bad as or worse for your lungs than smoking cigarettes.
- **Truth:** A study of 5,000 young adults in four cities over two decades recently published (1/10/12) in the Journal of the American Medical Association (JAMA) found that with regular use (a joint a day or up to three joints a week), the lung function of Marijuana smokers actually improved over time (16). The same study saw lung function drop significantly for cigarette smokers.
- **Myth:** Marijuana causes cancer
- **Truth:** Medical Marijuana does not cause cancer, and there is research to support the hypothesis that it can help cure different kinds of cancer (colon, breast, and skin) (17).
- **Myth:** Marijuana is a “gateway drug” that leads to heroin, cocaine, or crack (18)
- **Myth:** Marijuana causes memory diseases, such as Alzheimer’s, Parkinson’s or Huntington’s.
- **Truth:** Medical Marijuana does not cause Alzheimer’s, Parkinson’s or Huntington’s diseases, but it can relieve the symptoms of these diseases and sound scientific studies provide evidence that it can be preventative (19).
• **Myth:** Smoking high THC Marijuana gives you all the medicinal benefits that Medical Marijuana has to offer.

• **Truth:** Smoking high THC doesn’t access all the medicinal benefits that Medical Marijuana has to offer. Research shows that patients who just smoke high-THC Medical Marijuana are accessing only a quarter of the medicinal value of Medical Marijuana, and too much THC can imbalance the system so that frequent users of High THC Marijuana are prone to paranoia (20).

• **Myth:** The Marijuana “experience” is dose dependent and context independent.

• **Truth:** The Medical Marijuana “experience” is a function of three factors (21).
  
  o Dose (metabolic “state” of the system)
  o Set (internal landscape)
  o Setting (external landscape).

Medical Marijuana is Bi-Phase (22). This means that at high levels, it produces the opposite effects i.e. euphoria can turn into paranoia (23) and anti inflammation can turn into inflammation (24). Too much of anything, including Medical Marijuana, is a problem. However, if you understand how Medical Marijuana works, you can minimize the negative and enhance the positive. If Medical Marijuana is used effectively, it will help you find your natural balance, and as that balance emerges your use of Medical Marijuana will decrease as your feeling of well-being increases.

**How to Get the Medicinal Effects you are looking for**

The effects of Medical Marijuana vary greatly. The two explanations for the different effects are the different “strains” or “cannabinoids”. The Cannabis Culture (Collectives, Dispensaries, Growers, and Patients) uses the strain explanation – different effects are produced by different strains - Indica or Sativa. The scientific community (Researchers, Laboratories, and Pharmaceutical Companies) use the “cannabinoid” explanation – different effects are achieved by the use of different cannabinoids (Delta 9 Tetrahydro-Cannabinol i.e. THC or Cannabidiol i.e. CBD). Both explanations are useful and patients will benefit from Medical Marijuana therapies (Chart #1 and Chart #2) based on either or both. Below is a summary of each explanation from a medicinal and scientific perspective.

**Strains (25).**

**How do Strains Work?**

According to the Cannabis Culture (CC), “strains” are the key to medicinal benefits. Each strain is a unique combination of compounds in the cannabis plant. The unique compounds that belong to the Marijuana plant are called “cannabinoids,” and the most dominant are Tetrahydrocannabinol (THC) and Cannabidiol (CBD), although there are certainly others. Scientific research has revealed how THC and CBD work (the “Mechanism of Action”) which is outlined below. The CC believes that the terpenes and the other compounds contained in the natural plant (26) have an important influence. At present we do not know how the cannabinoids,
the terpenes and the other compounds work together in the particular strains but research is currently being performed in this area (27).

There is a common belief in the CC that Indicas have a higher level of cannabinoids than sativas and that they contain more CBD than Sativas. I have not been able to verify these beliefs. In fact, in my survey (Chart #3) of strain cannabinoid content there was no statistical difference between Indica and Sativa in terms of Cannabinoid content, though Sativa strains had more CBD than Indica strains.

**Indica strains** (28), according to the CC, are sedatives/relaxants and are effective for treating the symptoms of medical conditions such as anxiety, chronic pain, insomnia, muscle spasms and tremors. Common strains include:

- B-Dawg (23% THC/1% CBD)
- Granddaddy Purple (21% THC/1% CBD)
- Black Domina (21% THC/1% CBD)
- Purple Kush (19% THC/1% CBD)
- Purple OG Kush (14% THC/1% CBD)

**Sativa strains** (29) according to the CC, are a stimulant, and are effective in appetite stimulation, relieving depression, migraines, chronic pain and nausea. Common strains include:

- Green Dragon (22% THC/1% CBD)
- Sour Flower (20% THC/1% CBD)
- Pineapple (18% THC/1% CBD)
- Maui Wowie (16% THC/1% CBD)
- Super Sliver Haze (15% THC/1% CBD)

The CC believes that sativa strains cause feelings of alertness and optimism, and they recommend that patients medicate with this type of Medical Marijuana during the day.

**Hybrid strains** (30) are cross-breeds of Indica and Sativa strains that produce varieties that carry some characteristics of each parent. For example, the CC believes that adding Sativa to Indica strains adds mental clarity and decreases sedation effects. And, adding Indica to Sativa strains can decrease or even eliminate the Sativa tendency to stimulate anxiety (31). Common hybrid strains include:

- Sour Diesel (24% THC/2% CBD)
- Lavender (22% THC/1% CBD)
- Space Queen (19% THC/1% CBD)
- OG Kush (19% THC/1% CBD)
- Blueberry Diesel (15% THC/1% CBD)

Hybrids are often referenced based upon the dominant sub-species inherited from their lineage, e.g. Pure Indica, Mostly Indica, Mostly Sativa, or Pure Sativa. Instead of using pure Indica or pure Sativa, many patients can benefit from the use of hybrid strains. There are a vast number of strains available for patients, and while the ratios of THC to CBD are similar across Indica and
Sativa strains, the different effects lies with different cannabinoid profile (CBC, CBG, THCV etc) and the affects of terpenes.

**Cannabinoids**

Scientific research has discovered over 108 cannabinoids as of 2014. THC and CBD are the two dominant cannabinoids across all Marijuana Strains. Over 95% of the research has focused on THC and CBD. The medicinal effects unique to THC and CBD outlined below are based on the general principals uncovered by scientific analysis over the past 50 years. That research was made available to a layman through the pioneering work of Martin Lee, Fred Gardner and Ethan Russo (32) and publications such as O'Shaughnessy’s and web sites such as ProjectCBD ([www.projectcbd.org](http://www.projectcbd.org)). What follows is my understanding of the research presented in the publications mentioned above, the patents submitted by GW Pharmaceutical between 2003 and 2012, and my personal experience since 1996 under my doctor’s approval and oversight (33).

**How do Cannabinoids Work?**

Cannabinoids work by influencing the Endo-Cannabinoid System (34). The Endo-Cannabinoid system (ECS) refers to a group of endogenous lipid signaling molecules and their receptors. The term "endocannabinoid" is derived from the word "endogenous" (meaning "originating from within an organism") and "cannabinoid" (referring to the molecular compounds unique to Marijuana). The ECS regulates the activity both within and between the central nervous system (CNS) (35) and the peripheral nervous system (PNS) (36).

Cannabinoid receptors are a class of cell membrane receptors in your ECS. There are currently two known subtypes, termed CB1 and CB2 (37).

- CB1 receptors are expressed mainly in the brain and spinal column but also in the lungs, liver and kidneys. CB1 receptors mediate the activity generated by the central nervous system.
- CB2 receptors are expressed in the immune system and in hematopoietic cells. CB2 receptors mediate the activity in the peripheral nervous system.

The first pass of the metabolic process hydrolyzes (adds hydrogen) the cannabinoids to create active compounds that effect (stimulate or inhibit) ECS receptors. CBD and the first pass metabolites of CBD also bind to (stimulate) receptors outside the ECS system such as:

- TRPV-1 : pain perception, inflammation and body temperature (38)
- A2A : anti-inflammation and anti anxiety by mediating dopamine and glutamate indirectly (39)
- 5-HTP: anxiety, addiction, appetite, sleep, pain perception, nausea, vomiting (40)
- GPR55: modulates blood pressure and bone density (41)

The second pass of the metabolic process oxidizes (adds oxygen) to create compounds that inhibit inflammatory enzymes (42).
**Effects Unique to THC**

To understand the medicinal benefits of the primary cannabinoids (THC and CBD) it is useful to divide its effects into two categories; those effects that are unique to THC and CBD (and their metabolites) and those effects that are delivered by both THC and CBD. THC and its first metabolite (11-OH-THC) stimulate (i.e. agonist) the CB$_1$ receptor which mediates the activity (mental activity) in the central nervous system. They also stimulate CB$_2$ but not as strong as the effect on CB$_1$ (43). The second metabolite of THC (THC-COOH) provides anti-inflammation effects by inhibiting COX-1 and COX-2, (44)(45).

- Psychoactive (46) (47)
- Appetite Stimulate (48)
- Night Vision (49)
- Tachycardia (50)

**Effects Unique to CBD**

CBD and its first metabolite 7-OH-CBD reduces (it is an antagonist) the activity of the CB$_1$ receptors thereby reducing mental activity. They also increase the levels of endo-cannabinoids in the system that stimulates the ECS brain receptors (CB$_1$ and CB$_2$) by inhibiting the enzymes that destroy them (51).

- Anti-Psychotic (52) (53)
- Appetite Suppressant (54)
- Anti-depressant (55)
- Bradycardia (56)

**Effects of both THC and CBD**

Combining THC and CBD delivers the effects of THC and CBD (and their metabolites). Research has shown that there is a synergistic (1+1=5) effect when you combine THC and CBD. When THC and CBD are combined the negative effects of each (paranoia/ memory extinction) are reduced and positive medicinal benefits outlined below are increased.

- Anti-Inflammatory (57)
- Anticonvulsant (Spasticity) (58)
- Muscle Relaxant (59)
- Neuroprotective Antioxidant (60)
- Antiemetic (61)
- Antinociceptive (62)
- Anti-Glaucoma (64)
How should I use Cannabinoids?

While the general effects have been articulated, each individual is a special case (i.e. variation) of the general principal. For example, for most people CBD generates an increase in alertness, but there are some who take CBD and fall asleep almost immediately. And for most people THC is sedative, but there are some who cannot sleep after taking THC. This is because the metabolism of each human is unique (like fingerprints) and the only way to know for sure what the effects will be for you is to test the general principal on your unique metabolism.

Given that each individual is a special case of the general effects how does one determine what is the best for their unique metabolism? The only way to find out is to test what works via self-titration (personal trial and error).

The easiest way to understand how THC and CBD work together is to look at THC as the Agonist (i.e. stimulant mental activity) and CBD as the Antagonist (suppresses mental activity). THC is psychoactive, while CBD is anti-psychotic.

<table>
<thead>
<tr>
<th>THC = Agonist</th>
<th>CBD = Antagonist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase Mental Activity</td>
<td>Decrease Mental Activity</td>
</tr>
<tr>
<td>Psychoactive</td>
<td>Anti-psychotic</td>
</tr>
<tr>
<td>CNS stimulate</td>
<td>Anti-Depressant</td>
</tr>
<tr>
<td>Appetite Stimulate</td>
<td>Appetite Suppressant</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>Bradycardia</td>
</tr>
</tbody>
</table>

According to Traditional Chinese Medicine (65) when the active (Agonist) and deactivating (Antagonist) forces are balanced, the living system exhibits physical health; when they are unbalanced, a diseased state results. Either imbalance results in physical illness. If one goes too far one direction i.e. too much stimulation (Agonist) with THC and paranoia emerges (too much thinking), or too much Suppression (Antagonist) with CBD and memory extinction emerges (no thinking), then they can simply balance with the opposite. In addition to the medicinal benefits (refer to Chart #2) outlined above, there are five unique ways of combining THC and CBD to balance your CNS and PNS:

- THC alone
- CBD alone
- THC and CBD at the same time
- THC followed (wait 15 minutes) with CBD
- CBD followed (wait 15 minutes) with THC

What is the best? Only you can answer that question via the process of self-titration. I suggest that you start with the cannabinoid (THC or CBD) or a combination of THC/CBD that the research indicated has the highest medicinal effects you seek.
For instance, patients with a migraine seeking relief to tension in their CNS need to activate their CB₁ receptor and would start with THC. Two signs will appear that are a warnings signals that the intake of THC should be reduced:

- Issues (analysis paralysis, spacey etc.) caused by thinking too much
- Paranoia
- Insomnia

To reduce the paranoia induced by THC, add CBD and the paranoia will disappear within 10 minutes. Another example is someone who is depressed and is seeking relief, they should start with high CBD and add high THC if the effects of CBD need to be reduced. For example, two signs appear with frequent use of CBD:

- Issues (forgetfulness, anxious) caused by not thinking enough
- Memory Extinction
- Insomnia

If short term memory extinction occurs and it does not suit your needs, the active mind can be stimulated by taking THC.

Another example concerns Multiple Sclerosis, Alzheimer’s, and Parkinson’s diseases. Someone who is seeking relief from spasticity wants to maximize the anti-convulsant effects of cannabinoids should start with 50% THC and 50% CBD. As outlined above, when you combine THC and CBD you maximize the anti-consultant effects and minimize the negative of THC or CBD alone. If they find that they need to be active we suggest that they add CBD, on the other hand if they need to be passive (rest) we would suggest that they add THC.

If you go too far one direction i.e. too much agonist with THC and paranoia emerges, or too much antagonist with CBD and memory extinction emerges, simply balance with the opposite.
# Chart #1: Medical Marijuana Therapy
## Indica and Sativa Treatments

Vertical: Target Symptoms  
Horizontal: Strains

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Indica</th>
<th>Sativa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td></td>
<td><strong>X</strong></td>
</tr>
<tr>
<td>Appetite Stimulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic Pain</td>
<td><strong>X</strong></td>
<td><strong>X</strong></td>
</tr>
<tr>
<td>Depression</td>
<td></td>
<td><strong>X</strong></td>
</tr>
<tr>
<td>Insomnia</td>
<td><strong>X</strong></td>
<td></td>
</tr>
<tr>
<td>Migraines</td>
<td></td>
<td><strong>X</strong></td>
</tr>
<tr>
<td>Muscle Spasms</td>
<td><strong>X</strong></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td></td>
<td><strong>X</strong></td>
</tr>
<tr>
<td>Sedative</td>
<td><strong>X</strong></td>
<td></td>
</tr>
<tr>
<td>Stimulant</td>
<td></td>
<td><strong>X</strong></td>
</tr>
<tr>
<td>Tremors</td>
<td><strong>X</strong></td>
<td></td>
</tr>
</tbody>
</table>
### Chart #2: Medical Marijuana Therapy

**THC and CBD Treatments**

**Vertical:** Target Diseases
**Horizontal:** Chemo Type: Classes based on THC/CBD ratios

<table>
<thead>
<tr>
<th>Additional Info</th>
<th>High THC Agonist</th>
<th>50/50</th>
<th>High CBD Antagonist</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADD (66)</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>ADHD (67)</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>AIDS (68)</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Alzheimer’s (69)</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Arthritis (70)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer Pain / Chemo (71)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colon (72)</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Breast (73)</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Skin (74)</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Depression (75)</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Diabetes (76)</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Epilepsy (77)</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Fibromyalgia (78)</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Glaucoma (79)</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Huntington (80)</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Irritable Bowel Diseases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crohn’s disease (81)</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Ulcerative Colitis (82)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Migraines (83)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Motor neuron diseases (ALS) (84)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple Sclerosis (85)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea (86)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osteoarthritis (87)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parkinson’s (88)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psoriasis (89)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTSD (90)</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Withdrawal symptoms reduction (91)</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>
Chart #3: Medical Marijuana Survey Winter 2012

Vertical: Cannabis Strain (Indica/Hybrid/Sativa)  
Horizontal: Chemo Type: Classes based on THC/CBD ratios

<table>
<thead>
<tr>
<th>High THC</th>
<th>50/50</th>
<th>High CBD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agonist</td>
<td>Agonist/Antagonist</td>
<td>Antagonist</td>
</tr>
</tbody>
</table>

**Indica**
- B-Dawg 23/1
- Granddaddy Purple 21/1
- Black Domina 21/1
- Purple Kush 19/1
- Purple OG Kush 14/1

**Hybrid**
- Sour Diesel 24/2
- Trident 6/12
- Cannatonic 1/16
- Lavender 22/1
- Space Queen 19/1
- OG Kush 19/1
- Blueberry Diesel 15/1

**Sativa**
- Green Dragon 22/1
- Harlequin 6.5/8.5
- Harlequin 6/11
- Sour Flower 18/1
- Pineapple 18/1
- Maui Wowie 16/1
- Super Sliver Haze 15/1

**Note:**

1. *All cannabinoid medicine has a therapeutic widow, there is a minimum below which it is not effective (usually 5 mg/ml) and a maximum (usually 60 mg/ml) above which the medicine generates the opposite effects that the patient is looking for (Bi- Phasal).*
2. *How Cannabinoid Therapy affects children under the age of puberty is very different than children over the age of puberty. The reason for this is in order to experience CNS effects your brain receptors have to be developed and they are not developed until puberty (92). This means that children under the age of puberty can't get “high” because their neurotransmitters are not yet fully developed.*
Footnotes:

1. **CBD Science, LLC;** [www.cbdsience.com](http://www.cbdsience.com) is a consulting firm that advises Non-Profit Collectives (legal under state law and federally endorsed by the Ogden Memo of October 2009) on the development and production of safe and effective Cannabis Based Medicinal Extracts (CBME’s).
2. **The FDA position on Medical Marijuana:** FDA interagency Advisory 4-20-2006; [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108643.htm](http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108643.htm)
3. **The DEA position on Marijuana;** [http://www.justice.gov/dea/marijuana_position.pdf](http://www.justice.gov/dea/marijuana_position.pdf); Both the DEA and the FDA are taking positions in opposition to smoked Medical Marijuana, while at the same time, it appears as though they are leaving the “door” open for medicinal value of the “compounds” contained in Marijuana. This radical shift from, Medical Marijuana has no medicinal value, to the components of Medical Marijuana have medicinal value, is welcome but their position on smoked Medical Marijuana is weakened by recent study by the *Journal of the American Medical Association*, published on Jan. 11, 2012, which states; “experts have worried that the kinds of lung damage caused by cigarettes could also be brought on by pot smoking. Indeed, cigarette smokers in the study saw their lung function drop significantly over 20 years. But that didn’t happen to people who only smoked marijuana. In fact, the study found that the lung function of most marijuana smokers actually improved slightly over time.”
5. Refer to Footnote #4 and additional research resources below funded by NIH.
6. Department of Health and Human Services holds US patent 6,630,507, entitled “Cannabinoids as antioxidants and neuro-protectants” and is considering granting an exclusive patent license to Kannalife Sciences, Inc of New York to develop Cannabinoid therapeutics.
9. Refer to footnote #15; The United States Patent Office has granted over 10 patents and accepted over 30 applications for patents for GW Pharmaceuticals CBME’s between 2003 and 2012.
11. Footnote #1
12. Footnote #2

**Cannabis Related Patents 2003 to 2012:**

<table>
<thead>
<tr>
<th>Patent</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. 6630507</td>
<td>October 7, 2003: US Government Dept of Health and Human Services</td>
</tr>
<tr>
<td>2. 6730330</td>
<td>May 4, 2004: GW Pharmaceuticals</td>
</tr>
<tr>
<td>3. 6946150</td>
<td>September 20, 2005: GW Pharmaceuticals</td>
</tr>
<tr>
<td>4. 7025992</td>
<td>April 11, 2006: GW Pharmaceuticals</td>
</tr>
<tr>
<td>5. 7344736</td>
<td>March 18, 2008: GW Pharmaceuticals</td>
</tr>
<tr>
<td>6. 7622140</td>
<td>November 24, 2009: GW Pharmaceuticals</td>
</tr>
<tr>
<td>7. 7674922</td>
<td>March 9, 2010: Albany Molecular Research, Inc.</td>
</tr>
<tr>
<td>8. 7700368</td>
<td>April 20, 2010: GW Pharmaceuticals</td>
</tr>
<tr>
<td>10. 7968594</td>
<td>June 28, 2010: GW Pharmaceuticals</td>
</tr>
<tr>
<td>11. 8034843</td>
<td>October 11, 2011 : GW Pharmaceuticals</td>
</tr>
</tbody>
</table>

**Cannabis Related Patent Applications 2003 to 2012**

<table>
<thead>
<tr>
<th>Application</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. 20030191180</td>
<td>October 9, 2003: GW Pharmaceuticals</td>
</tr>
<tr>
<td>2. 20040049059</td>
<td>March, 11, 2004: GW Pharmaceuticals</td>
</tr>
</tbody>
</table>
Dr. Sean McAllister on THC and CBD and Neuroinflammation

Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation

Daniel K Nomura, Bradley E Morrison, Jacqueline L Blankman, Jonathan Z Long,

Russo, E., “The Entourage Effect” O’Shaughnessy Autumn 2011-12-14 Page 1

Dr. Allan Frankel [http://www.greenbridgemed.com/](http://www.greenbridgemed.com/)

Indica: [https://www.marijuanadoctors.com/content/resources/cannabis-indica-vs-sativa](https://www.marijuanadoctors.com/content/resources/cannabis-indica-vs-sativa)

Sativa: [https://www.marijuanadoctors.com/content/resources/cannabis-indica-vs-sativa](https://www.marijuanadoctors.com/content/resources/cannabis-indica-vs-sativa)

Hybrid: [https://www.marijuanadoctors.com/content/resources/cannabis-indica-vs-sativa](https://www.marijuanadoctors.com/content/resources/cannabis-indica-vs-sativa)

I have not been able to validate or refute these beliefs


http://en.wikipedia.org/wiki/Martin_A._Lee


My personal physician of over 15 years (not a “Pot Doc”) has been overseeing my cannabis therapy and in my case she continues to recommend its use.


CBD: How it works, Martin A Lee. O’Shaughnessy’s Autumn 2011-12-14

Refer to Footnote # 38

Refer to Footnote # 38

Refer to Footnote # 38

Evaluation of the Cyclooxygenase (COX-1 and COX-2) Inhibiting Effects of Six Major Cannabinoids Isolated from Cannabis sativa; Ruhaak et al 2011

Showalter VM, Compton DR, Martin BR, Abood ME

The Cannabinoid Trail: Albert L Coles, Jr CBD Science, unpublished December, 2011 NOTE: THC-COOH converts to THC via decarboxylation (remove Co2), THC converts to 11-OH-THC in the first pass of the metabolic process via hydroxylation (add OH), 11-OH-THC coverts to THC-COOH is the second stage of the metabolic process via oxidation (add Co2). THC-COOH to THC to 11-OH-THC to THC-COOH: CBD-COOH to CBD to 7-OH-CBD to CBD-COOH?

Refer to Footnote #42


Russo EB, Merzouki A, Molero Mesa J, Frey KA, Bach PJ. 2004

Karniol IG, Shirakawa I, Kasinski N, Pfefferman A, Carlini EA. 1974

CBD: How it works, Martin A Lee. O’Shaughnessy’s Autumn 2011-12-14

Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. 1995; Moreira FA, Guimaraes FS. 2005

Mechoulam: O’Shaughnessy’s Journal Winter/Spring 2008 Effects of CBD increases wakefulness

Mechoulam R

Zuardi AW, Guimaraes FS. Cannabidiol as an anxiolytic and antipsychotic. 1997

Weil AT, Zinberg NE, Nelsen JM

E Russo and G Guy “A Tale of Two Cannabinoids” August 2005

Hampson AJ, Grimaldi M, Axelrod J, Wink D


Collin C. 2005

Hampson AJ, Grimaldi M, Axelrod J, Wink D


Pertwee RG. Cannabinoid receptors and pain. 2001

Jarvinen T, Pate D, Laine K. 2002
65. Traditional Chinese Medicine
http://en.wikipedia.org/wiki/Chinese_Medicine also refer to the "Principal of Complementary" R. Buckminster Fuller, "Conversations with Bucky"
https://conversationswithbucky.pbworks.com/w/page/16447435/FrontPage

66. ADD
a. David Bearman MD, has done the most work on marijuana and attention deficit and hyperactivity disorders. Unfortunately, the evidence at present is anecdotal though the science of the ENS supports the hypotheses that self titration with both THC and CBD will help those who are imbalanced

67. ADHD Refer to Footnote #55

68. AIDS:


69. Alzheimer's


70. Arthritis


72. Cancer Breast:
   a. Dr. Sean McAllister http://www.cpmc.org/professionals/research/programs/science/sean.html Dr. Sean McAllister on THC and CBD and Cancer:
http://www.youtube.com/watch?v=drW12wqbwU


73. **Cancer Colon**: Cannabinoids Inhibit Insulin Receptor Signaling in Pancreatic B-Cells, Kim et al Fed

74. **Cancer Skin**:
   b. Antidotal evidence http://www.youtube.com/watch?v=0tghUh4ubbg

75. **Depression**

76. **Diabetes**:


80. **Huntington's**
   a. US Patent 5,538,993 Mechoulam et al 1994 Prospects for cannabinoid therapies in basal ganglia disorders Javier Fernández-Ruiz, Miguel Moreno-Martet, Carmen Rodríguez-Cueto, Cristina Palomo-Garo, María Gómez-Cañas, Sara Valdeolivas, Carmen Guaza, Julián Romero, Manuel Guzmán, Rafael Mechoulam and José A Ramos


Recent Research on Sativex

Current clinical research on the medical use of cannabis in the United States: Historical Perspectives, Current Trends, and future Prospects for cannabinoid therapies in basal ganglia disorders


Additional References:

1. The Endocannabinoid System as an Emerging Target of Pharmacotherapy: Pancher NIH 2006
2. How Cannabis Works http://www.youtube.com/watch?v=hpV6licCOMw
4. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb Angelo A. Izzo1,4, Francesca Borrelli1,4, Raffaele Capasso1,4, Vincenzo Di Marzo2,4 and Raphael Mechoulam
5. Cannabinoids in medicine: A review of their therapeutic potential 2006 Mohamed Ben Amar
9. New York Times Magazine January 7, 2011 “There’s evidence that shows that it’s useful for medicine, but we need to investigate how to avoid the adverse effects of smoking marijuana”, Vice Admiral Vice l Regina Benjamin. United States Surgeon General”

Videos

1. Mechoulam R http://www.youtube.com/watch?v=Wmqh1Q2cnD0
Additional Research Resources:

23. Zuardi AW, Karniol IG. Effects on variable-interval performance in rats of delta 9-
24. Rosenkrantz H, Hayden DW. Acute and subacute inhalation toxicity of Turkish marihuana, 
33. Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. Influence of cannabidiol on delta-9-
34. Lemberger L, Dalton B, Martz R, Rodda B, Forney R. Clinical studies on the interaction of 
35. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ. The endogenous cannabinoid system 
results from 12 months follow-up. Mult Scler 2004;10(Suppl.):S115.
45. Guy GW, Flint ME. A single centre, placebo-controlled, four period, crossover, tolerability study 
assessing pharmacokinetic effects, pharmacokinetic characteristics and cognitive profiles of as single 
dose of three formulations of cannabis based medicine extracts (CBMEs) (GWP9901), plus a two 
period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of


59. Robson P, Wade D, Makela P, House H, Bateman C. Cannabis-based medicinal extract (Sativex) produced significant improvements in a subjective measure of spasticity which were maintained on long-term treatment with no evidence of tolerance. In: International Association for Cannabis as Medicine; Leiden, Netherlands; 2005 September 9.


*Adapted From “Tale of Two Cannabinoids”. Russo, E, Guy, G. 2006

©2012 CBD Science, LLC, All rights reserved.
Disclosure: Albert L. Coles, Jr does not provide medical advice, diagnosis or treatment. The contents of this paper, such as text, graphics, images, and other material contained on the Alta-California web site (www.4altacalifornia.com) and the CBD Science, LLC web site (www.cbdscience.com) (“Content”) are for
informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this paper or on the web sites!

If you think you may have a medical emergency, call your doctor or 911 immediately. Albert L Coles, Jr does not recommend or endorse any specific tests, physicians, dispensaries, products (other than Alta-California), procedures, opinions, or other information that may be mentioned in this paper or on the sites. Reliance on any information provided by Albert L Coles, Jr, CBD Science LLC employees, others references appearing in this paper are solely at your own risk.